An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort
Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen B, North Central Cancer Treatment Group
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 172 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Cancer Institute
- Gobierno
- NCI NIH HHS
- Subvenciones
- National Cancer Institute (CA 35101); National Cancer Institute (CA- 35113); National Cancer Institute (CA- 35269); National Cancer Institute (CA35103); National Cancer Institute (CA35195); National Cancer Institute (CA 52352); National Cancer Institute (CA35272); National Cancer Institute (CA37417); National Cancer Institute (CA-63849); National Cancer Institute (CA35448); National Cancer Institute ((CA-25224); National Cancer Institute (CA-37404); National Cancer Institute (CA 63826); National Cancer Institute (CA 60276); National Cancer Institute (CA 15083); National Cancer Institute (CA-63848)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2004-06-15 · J Clin Oncol · vol. 22 · número 12 · págs. 2469–2476
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 296 citas · más que el 100% de estudios similares · 17.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 26 trabajos
- Acceso
- De pago
- Áreas de investigación
- Nutrition and Health in Aging · Clinical Nutrition and Gastroenterology · Fatty Acid Research and Health
- Palabras clave
- eicosapentaenoic acid, omega-3 fatty acids, megestrol acetate, cachexia, weight gain, appetite stimulation, dietary supplementation, combination therapy, survival, quality of life, erectile dysfunction
- MeSH
- humans, neoplasms, wasting syndrome, body weight, megestrol acetate, eicosapentaenoic acid, appetite stimulants, survival rate, appetite, quality of life, dietary supplements, aged, middle aged, canada, female, male
12 autores
- Aminah Jatoi🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Kendrith M. Rowland🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Charles L. Loprinzi🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Jeff A. Sloan🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Shaker R. Dakhil🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Neil Macdonald🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Bruno Gagnon🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Paul J. Novotny🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- James A. Mailliard🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Teresita I.L. Bushey🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Suresh Nair🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
- Brad Christensen🇺🇸🇨🇦Mayo Clinic; Missouri Valley Cancer Consortium; Cancer Center of Kansas; McGill University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Studies suggest eicosapentaenoic acid (EPA), an omega-3 fatty acid, augments weight, appetite, and survival in cancer-associated wasting. This study determined whether an EPA supplement-administered alone or with megestrol acetate (MA)-was more effective than MA.
Patients and methods
Four hundred twenty-one assessable patients with cancer-associated wasting were randomly assigned to an EPA supplement 1.09 g administered bid plus placebo; MA liquid suspension 600 mg/d plus an isocaloric, isonitrogenous supplement administered twice a day; or both. Eligible patients reported a 5-lb, 2-month weight loss and/or intake of less than 20 calories/kg/d.
Results
A smaller percentage taking the EPA supplement gained >or= 10% of baseline weight compared with those taking MA: 6% v 18%, respectively (P =.004). Combination therapy resulted in weight gain of >or= 10% in 11% of patients (P =.17 across all arms). The percentage of patients with appetite improvement (North Central Cancer Treatment Group Questionnaire) was not statistically different: 63%, 69%, and 66%, in EPA-, MA-, and combination-treated arms, respectively (P =.69). In contrast, 4-week Functional Assessment of Anorexia/Cachexia Therapy scores suggested MA-containing arms experienced superior appetite stimulation compared with the EPA arm, with scores of 40, 55, and 55 in EPA-, MA-, and combination-treated arms, respectively (P =.004). Survival was not significantly different among arms. Global quality of life was not significantly different among groups. With the exception of increased impotence in MA-treated patients, toxicity was comparable.
Conclusion
This EPA supplement, either alone or in combination with MA, does not improve weight or appetite better than MA alone.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.